Intergroup Rhabdomyosarcoma Study Group: Late Effects After Treatment for Rhabdomyosarcoma
OBJECTIVES: I. Determine the frequency of self reported health related outcomes in patients
with rhabdomyosarcoma who survived 5 years from diagnosis after treatment on Intergroup
Rhabdomyosarcoma Study Group (IRSG) protocols I, II, III, and IV pilot. II. Determine the
mortality of these patients and compare this mortality to the general population, especially
in the third and fourth decades of life. III. Determine treatment specific risks of
developing a second malignancy following treatment of rhabdomyosarcoma and the potential
genetic influences (family history of cancer). IV. Determine the association between
decreased fertility/offspring and dose, schedule, and total dose of alkylating agents
(especially cyclophosphamide) received during treatment and with selected genitourinary and
paratesticular primaries. V. Determine the effect of the dose and location of therapeutic
radiation for primary head and neck cancer on achieved final height. VI. Determine the
association of therapy with doxorubicin (dose and age when received) with cardiac and
vascular events.
OUTLINE: Patients (or parent or surviving family member) complete the baseline questionnaire
plus other questionnaires (offspring, family history, other topic specific). Medical data is
also collected from past records.
PROJECTED ACCRUAL: Approximately 1600 patients will be accrued for this study.
Interventional
Primary Purpose: Supportive Care
William M. Crist, MD
Study Chair
University of Missouri-Columbia
United States: Federal Government
CDR0000066945
NCT00003801
Name | Location |
---|